In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unsettled

Executive Summary

Few industry executives believe the settlement of litigation between independent pharmacists and drug cpompanies itself will change company pricing practices; if anything, the court emphatically affirmed that differential pricing supports, rather than undermines, a competitive marketplace.

You may also be interested in...



Drug Firms Fear PBM ‘Discrimination’ Over List Price Reductions, Azar Tells Hearing

HHS Secretary Azar explains why companies have not voluntarily lowered prices as yet, despite President Trump’s recent comments. He also discussed using regulations to prohibit rebates.

A World Without Rebates: Is FDA’s Gottlieb Offering New Vision?

US FDA Commissioner Gottlieb suggests administrative action to prohibit drug rebates as a way to lower drug prices. His remarks may preview an upcoming proposal from President Trump and HHS Secretary Azar.

Korean Biopharma Today And Tomorrow: M&A, Investment, Governance

Experts shared views at a recent conference in Seoul on how the Korean biopharma industry has evolved and what needs to be done to move forward in the next 10 years. Policy efficiency and family ownership in the sector came in for particular scrutiny, with some calling for sweeping changes. 

Topics

Latest News
See All
UsernamePublicRestriction

Register

IV000531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel